ArticleFrontiers in immunology2024

Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression.

Oanh T P Nguyen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.